- Home
- NTRB vs RLYB Comparison
NTRB vs RLYB Comparison
Compare NTRB & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- RLYB
- Stock Information
- Founded
- NTRB 2016
- RLYB 2018
- Country
- NTRB United States
- RLYB United States
- Employees
- NTRB N/A
- RLYB N/A
- Industry
- NTRB Industrial Specialties
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- RLYB Health Care
- Exchange
- NTRB Nasdaq
- RLYB Nasdaq
- Market Cap
- NTRB 77.9M
- RLYB 45.2M
- IPO Year
- NTRB N/A
- RLYB 2021
- Fundamental
- Price
- NTRB $4.08
- RLYB $0.95
- Analyst Decision
- NTRB
- RLYB Buy
- Analyst Count
- NTRB 0
- RLYB 6
- Target Price
- NTRB N/A
- RLYB $8.10
- AVG Volume (30 Days)
- NTRB 30.2K
- RLYB 106.4K
- Earning Date
- NTRB 12-04-2024
- RLYB 11-07-2024
- Dividend Yield
- NTRB N/A
- RLYB N/A
- EPS Growth
- NTRB N/A
- RLYB N/A
- EPS
- NTRB N/A
- RLYB N/A
- Revenue
- NTRB $2,021,771.00
- RLYB $598,000.00
- Revenue This Year
- NTRB N/A
- RLYB N/A
- Revenue Next Year
- NTRB N/A
- RLYB N/A
- P/E Ratio
- NTRB N/A
- RLYB N/A
- Revenue Growth
- NTRB N/A
- RLYB N/A
- 52 Week Low
- NTRB $2.22
- RLYB $0.93
- 52 Week High
- NTRB $9.60
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- NTRB 40.82
- RLYB 37.53
- Support Level
- NTRB $3.87
- RLYB $0.93
- Resistance Level
- NTRB $4.80
- RLYB $1.24
- Average True Range (ATR)
- NTRB 0.51
- RLYB 0.08
- MACD
- NTRB 0.04
- RLYB -0.02
- Stochastic Oscillator
- NTRB 21.21
- RLYB 6.45
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.